Climate Change Data

Environmental Metrics

Social Achievements

• Operational review yields $1.8 million in annualized cost savings, including 50% reduction in Board expense.
• Relocated from Hornsby to more economical premises at Barangaroo in Sydney.

Governance Achievements

• Updated its Board and Committee charters as part of an ongoing review of corporate governance.
• Shareholders approved a rebranding to Kazia Therapeutics Limited and a 10:1 ratio common stock consolidation.

Climate Goals & Targets

Environmental Challenges

• Long-term financing of the Company remains a key priority.
• Additional funding will likely be required in the next financial year to maintain progress in building pipeline value.

Mitigation Strategies

• Filed an F-3 ‘shelf’ registration with the US Securities and Exchange Commission to allow for placement of up to US$100 million of NASDAQ securities over the next three years.
• Deferred 50% of Non-Executive Directors' fees from 1 February 2018 to conserve cash resources.
• No cash bonuses were paid in respect of the financial year ended 30 June 2018 to conserve cash resources.
• Strategic decision to partner out legacy early-stage discovery programs to conserve resources and focus on near-term value creation.

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations

Third-party Assurance: Grant Thornton Audit Pty Ltd

Environmental Metrics

ESG Focus Areas

• Environment
• Society
• Governance

Environmental Achievements

• Kazia’s head office is located in the International Towers complex, which is 100% carbon neutral and the first location globally to receive a 100% climate resilience score from GRESB.

Social Achievements

• Kazia works closely with advocacy organisations and not-for-profit groups to help inform the community about the disease areas we work in.
• Kazia is attentive to the need for diversity in clinical trial recruitment, and works hard to ensure that its medicines eventually become accessible to the widest range of patients.
• Kazia has run a ‘compassionate use’ program, which can in rare cases make its drugs available to patients outside of clinical trials. To date, more than thirty patients in six countries have received paxalisib on a compassionate use basis.

Governance Achievements

• Kazia, as a company listed on both ASX and NASDAQ, respects the governance frameworks of both jurisdictions.
• Kazia has pre-emptively and voluntarily begun to implement a rigorous validation for vendors and partners, which includes compliance with Australia’s Modern Slavery Act 2018 (Cth).

Climate Goals & Targets

Environmental Challenges

• The news that paxalisib would not enrol the second stage of the GBM AGILE pivotal trial shook investor confidence.
• Extremely negative sentiment towards the biotech sector in the financial markets complicated Kazia’s funding cycle.

Mitigation Strategies

• Kazia’s strategy has always been to diversify its activities as broadly as possible, so that the company and its shareholders are insulated from adverse developments.
• Kazia implemented an ‘at-the-market’ (ATM) facility to provide interim access to capital through the market downturn.

Supply Chain Management

Climate-Related Risks & Opportunities

Environmental Metrics

ESG Focus Areas

• Climate Change
• Community Contribution
• Gender Equity
• Governance

Environmental Achievements

• Kazia head office is located in one of the most sustainable carbon neutral commercial precincts in the world. The serviced office is located in a building with a five‑star NABERS energy rating.
• Major partner Evotec, who is running our EVT-801 trial, is a signatory to the Science Based Targets initiative (SBTi) and is determined to become net carbon neutral by 2050.

Social Achievements

• Our compassionate program has treated over 40 patients in 7 countries since its inception in 2018.
• Kazia's board welcomed its first female member in 2023.

Governance Achievements

• As a company listed on both ASX and NASDAQ, we respect and comply with the governance frameworks of both jurisdictions.
• The following policies are in place and available on our website: Anti-Corruption Compliance, Continuous Disclosure, Corporate Governance, Expanded Access, Shareholder Communications, Whistleblower

Climate Goals & Targets

Environmental Challenges

• The entity is not generating revenues and is not expected to do so in the foreseeable future. There is material uncertainty which may cast significant doubt on whether the the consolidated entity will continue as a going concern.

Mitigation Strategies

• During the month of July 2023 through 7 August 2023, the Company raised total proceeds for the period of US$1,019,769 (A$1,540,918) using the ATM facility and continues to seek additional funding sources both in Australia and overseas.

Supply Chain Management

Climate-Related Risks & Opportunities